中国实用外科杂志2024，Vol.44Issue(2)：234-240,7.DOI:10.19538/j.cjps.issn1005-2208.2024.02.23
PD-1与PD-L1抑制剂在非转移性三阴性乳腺癌新辅助治疗应用进展
Research progress of PD-1 and PD-L1 inhibitors in neoadjuvant therapy of early triple-negative breast cancer
摘要
Abstract
The expression level and activity of tumor-infiltrating lymphocytes(TILs)in triple-negative breast cancer(TNBC)patients were significantly higher than those of other breast cancer sub-types,providing potential for immunotherapy.Multiple clinical trials have shown that PD-1 and PD-L1 inhibitors have achieved excellent therapeutic results in the neoadjuvant phase of non-metastatic TNBC.In addition,in the neoadjuvant phase,low-intensity chemotherapy combined with immunotherapy or dual immunotherapy without chemotherapy has a good therapeutic prospect and may be a future development trend.Different from metastatic TNBC,the specificity and sensitivity of PD-L1 to predict the efficacy of neoadjuvant immunotherapy in non-metastatic TNBC are relatively low.In the future,it is necessary to combine other immune markers and refine the TNBC classification,to select patients who can benefit from immunotherapy in a targeted manner,further improve the therapeutic value of PD-1 and PD-L1 inhibitors,and achieve precise treatment of TNBC.关键词
三阴性乳腺癌/非转移性乳腺癌/免疫治疗/联合治疗/程序性死亡受体-1/程序性死亡受体配体-1/预测标记物Key words
triple-negative breast cancer/non-metastatic breast cancer/immunotherapy/combination therapy/pro-grammed death 1/programmed death-ligand-1/predictive markers分类
临床医学引用本文复制引用
周思成,辛灵,叶京明,刘荫华..PD-1与PD-L1抑制剂在非转移性三阴性乳腺癌新辅助治疗应用进展[J].中国实用外科杂志,2024,44(2):234-240,7.基金项目
北京奖励基金会项目(No.YXJL-2020-0941-0736) （No.YXJL-2020-0941-0736）
中国乳腺外科青年医师研究项目(No.2020-CHPASLP-01,No.CJBSRAF-2022) （No.2020-CHPASLP-01,No.CJBSRAF-2022）
